BioPharmSignal logoBioPharmSignal

Biotech News

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

AnaptysBio, Inc. (ANAB)AnaptysBio, Inc.Company update

Strengthens Leadership Team and Board with additional business development, finance and royalty management expertise SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with

Related news

XFORX4 Pharmaceuticals2026-07-01 11:00 EST

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

KYMRKymera2026-07-27 20:01 EST

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

CLDXCelldex Therapeutics2026-07-15 20:01 EST

Celldex Announces Planned Transition of Chief Financial Officer

XLOXilio Therapeutics2026-06-29 11:30 EST

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

KYMRKymera2026-06-24 20:01 EST

Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors

BNTXBioNTech2026-08-03 09:00 EST

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

IMVTImmunovant2026-08-06 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

BNTXBioNTech2026-08-04 10:45 EST

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

View all latest news

AnaptysBio, Inc.

Biopharma Royalty Company Following the spin-off of First Tracks Biotherapeutics, AnaptysBio manages financial collaborations rather than operating an internal drug-development portfolio. Jemperli Economics Anaptys receives royalties tied to GSK’s Jemperli franchise, including development in endometrial, rectal, colon, and head and neck...

Recent company news

ANABAnaptysBio, Inc.2026-05-12 20:15 EST

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

ANABAnaptysBio, Inc.2026-05-11 13:15 EST

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

ANABAnaptysBio, Inc.2026-05-04 20:15 EST

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

ANABAnaptysBio, Inc.2026-04-24 19:40 EST

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim

ANABAnaptysBio, Inc.2026-04-20 13:15 EST

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

Stock data

Close
54.77 USD
Market cap
1.49B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States